Find and Join

News Logo

• Tattoos, legal counsel, and good info

  If APC had a tattoo on its bicep — if we had a bicep, I mean — it might well read “Consult legal counsel.” read more →

• State advocacy update

  APC sent a letter to the New Mexico Board of Pharmacy this week commenting on its proposed amendments that would align the state with USP (good), but would also require that pharmacists ensure all flavors are inert (yikes). read more →

• Board approves new officer succession

  The APC Board of Directors has voted to name Gina Besteman (previously vice president) the board chair-elect after the resignation of Michelle Moser from the position. Besteman will assume the chair in January 2025. read more →

• FDA is concerned about compounded GLP-1 dosing errors

  Earlier this week APC received a letter from the FDA explaining the agency's concerns regarding dosing and patient usage of compounded semaglutide and tirzepatide. read more →

• Did you get your Compounding Pharmacy Snapshot?

  If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America. read more →

• After report, FTC to sue PBMs

  On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs. read more →

More News

PCCA Ad

Blank

Medisca Ad

Blank

Fagron Ad

Blank

Wedgewood Ad

Blank

TopiClick Ad

APC and its longtime supporter Medisca have agreed to a five-year deal that includes Medisca’s five-year commitment as a Platinum-level APC Corporate Patron. The deal, valued at $300,000, includes an exclusive license for APC to use the compounding.com domain for its upcoming cBHT media campaign, as well as for any consumer-focused follow-on campaign aimed at elevating pharmacy compounding.

“We’re deeply grateful for this support from our friends at Medisca,” said APC’s CEO, Scott Brunner. “It’s a vote of confidence in the work APC is doing. We look forward to a productive partnership with Medisca as we defend pharmacy compounding and protect patient access to compounded preparations.”